Apellis Pharmaceuticals Inc
169 articles with Apellis Pharmaceuticals Inc
-
BioSpace Movers & Shakers, May 6
5/6/2022
Biopharma and life sciences companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers. -
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 06, 2022
5/6/2022
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to four new employees with a grant date of May 2, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference
5/5/2022
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company will present at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 8:40 a.m. PT.
-
Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results
5/4/2022
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced its first quarter 2022 financial results and business highlights.
-
Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company
5/3/2022
Apellis Pharmaceuticals, Inc. announced today that renowned hematologist Peter Hillmen, MB ChB, PhD, will join the company as head of hematology engagement, effective May 23, 2022.
-
Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
5/2/2022
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced detailed, longer-term data from the Phase 3 DERBY and OAKS studies of intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
-
Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results
4/26/2022
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022 at 4:30 p.m. ET.
-
Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)
4/21/2022
Apellis Pharmaceuticals, Inc. today announced results from a global survey conducted by The Harris Poll, which found that living with geographic atrophy (GA) can cause a substantial emotional burden and impact on independence.
-
Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
4/4/2022
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company will present at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 at 3:00 p.m. ET.
-
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock - Mar 24, 2022
3/24/2022
Apellis Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 7,446,809 shares of its common stock at a public offering price of $47.00 per share, for total gross proceeds of $350 million, before deducting underwriting discounts and commissions and expenses payable by Apellis.
-
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock - Mar 23, 2022
3/23/2022
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that it has commenced an underwritten public offering of $300 million of its common stock.
-
It was a busy week for clinical trial announcements. Here's a look.
-
Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
3/16/2022
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced longer-term data from the Phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan, an investigational, targeted C3 therapy, continued to reduce geographic atrophy (GA) lesion growth and demonstrate a favorable safety profile at month 18 for the treatment of GA secondary to age-related macular degeneration (AMD).
-
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - Mar 02, 2022
3/2/2022
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company will participate in the following investor conferences in March.
-
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
2/28/2022
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2021 financial results and business highlights.
-
Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results
2/22/2022
Apellis Pharmaceuticals today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2021 financial results on Monday, February 28, 2022 at 4:30 p.m. ET.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 06, 2022
1/6/2022
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to one new employee with a grant date of January 3, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the company.
-
Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/3/2022
Apellis Pharmaceuticals today announced that the company will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH
12/15/2021
The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS phase 3 study where Aspaveli demonstrated superiority to eculizumab in improving haemoglobin levels 1.